Radioiodine Therapy in Patient with Differentiated Thyroid Cancer and End-Stage Renal Disease on Maintenance Hemodialysis: Case Report with Review of Literature

J Nucl Med Technol. 2022 Sep;50(3):228-232. doi: 10.2967/jnmt.121.261979. Epub 2021 Dec 6.

Abstract

Surgical resection followed by radioactive iodine (131I) therapy constitutes a standard treatment for differentiated thyroid cancer. 131I is normally excreted through the kidneys, and treatment of patients with end-stage renal disease on hemodialysis requires special attention to the dose of 131I, the timing of dialysis, and radiation safety. We present a case of end-stage renal disease in a postthyroidectomy patient on hemodialysis who required radioactive iodine ablation, and we review the literature.

Keywords: ESRD; radioiodine therapy; thyroid cancer.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma*
  • Humans
  • Iodine Radioisotopes / therapeutic use
  • Iodine*
  • Kidney Failure, Chronic* / chemically induced
  • Kidney Failure, Chronic* / complications
  • Kidney Failure, Chronic* / drug therapy
  • Renal Dialysis
  • Thyroid Neoplasms* / radiotherapy

Substances

  • Iodine Radioisotopes
  • Iodine-131
  • Iodine